StreetInsider.com News Articles

Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

Wed, 28 May 2025 09:00:00 -0400

New technology has potential to accelerate timelines for therapeutic research and drug development

SAN DIEGO--(BUSINESS WIRE)-- Telesis Bio Inc. (OTCMKTS: TBIO), a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced a new license agreement with Regeneron Pharmaceuticals, Inc. to deploy Telesis Bio’s revolutionary Gibson SOLA™ platform at its R&D core facilities. This will help Regeneron adopt automated, high-throughput, on-demand gene synthesis in their own labs.

Using Gibson SOLA at scale is intended to contribute to an agile and efficient approach to biologics discovery. The Gibson

Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

Wed, 28 May 2025 09:00:00 -0400

New technology has potential to accelerate timelines for therapeutic research and drug development

Using Gibson SOLA at scale is intended to contribute to an agile and efficient approach to biologics discovery. The Gibson

Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

Wed, 28 May 2025 09:00:00 -0400

New technology has potential to accelerate timelines for therapeutic research and drug development

Using Gibson SOLA at scale is intended to contribute to an agile and efficient approach to biologics discovery. The Gibson

Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

Wed, 28 May 2025 09:00:00 -0400

New technology has potential to accelerate timelines for therapeutic research and drug development

Using Gibson SOLA at scale is intended to contribute to an agile and efficient approach to biologics discovery. The Gibson

Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

Wed, 28 May 2025 09:00:00 -0400

New technology has potential to accelerate timelines for therapeutic research and drug development

Using Gibson SOLA at scale is intended to contribute to an agile and efficient approach to biologics discovery. The Gibson

Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

Wed, 28 May 2025 09:00:00 -0400

New technology has potential to accelerate timelines for therapeutic research and drug development

Using Gibson SOLA at scale is intended to contribute to an agile and efficient approach to biologics discovery. The Gibson

Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

Wed, 28 May 2025 09:00:00 -0400

New technology has potential to accelerate timelines for therapeutic research and drug development

Using Gibson SOLA at scale is intended to contribute to an agile and efficient approach to biologics discovery. The Gibson

Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

Wed, 28 May 2025 09:00:00 -0400

New technology has potential to accelerate timelines for therapeutic research and drug development

Using Gibson SOLA at scale is intended to contribute to an agile and efficient approach to biologics discovery. The Gibson

Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

Wed, 28 May 2025 09:00:00 -0400

New technology has potential to accelerate timelines for therapeutic research and drug development

Using Gibson SOLA at scale is intended to contribute to an agile and efficient approach to biologics discovery. The Gibson

Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

Wed, 28 May 2025 09:00:00 -0400

New technology has potential to accelerate timelines for therapeutic research and drug development

Using Gibson SOLA at scale is intended to contribute to an agile and efficient approach to biologics discovery. The Gibson

Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis

Tue, 18 Mar 2025 09:00:00 -0400

SAN DIEGO--(BUSINESS WIRE)-- Telesis Bio, a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced that it has entered into a convertible preferred stock purchase agreement (the Purchase Agreement) to sell shares of a new series of convertible preferred stock in a private placement. The financing was led by Novalis LifeSciences and Northpond Ventures and is expected to result in gross proceeds to the Company of up to approximately $21 million.